
A Missouri court has approved payouts of up to $7.25 billion to settle lawsuits against the German conglomerate Bayer, brought by patients who were diagnosed with cancer after using the herbicide Roundup, the Associated Press reported.
The court’s decision confirms that Bayer failed to warn consumers that the weed-killing product could cause cancer, according to the Associated Press.
The payouts will apply to individuals who have been diagnosed with non-Hodgkin lymphoma, as well as those who may receive such a diagnosis in the future. Compensation will range from $10,000 to $165,000, depending on how the herbicide was used, when the diagnosis was made, and the severity of the illness.
The German company, which has since altered the formula of the product sold for retail use, denies any link between Roundup and the development of cancer. Attorneys for the plaintiffs are divided on the adequacy of the settlement amounts; some consider them insufficient, while others point out that, given certain U.S. Supreme Court rulings, there was a risk that plaintiffs might have received no compensation at all.
The $7.25 billion figure includes $600 million for legal fees. According to reports, the court’s decision will allow Bayer to plan its financial strategy following a long period of litigation—a situation that had previously led the company to consider withdrawing from the U.S. market. The judge emphasized that a different outcome could have pushed the conglomerate toward bankruptcy.
As reported by the newspaper VZGLYAD, the U.S. began reviewing more than 4,000 lawsuits against the manufacturers of the drug Ozempic earlier this month.
Over the summer, pharmaceutical giant Johnson & Johnson agreed to settle nearly 80,000 claims brought by consumers. In the spring, Indigenous Australians won $108 million in compensation from a mining company.